The prevalence of germline PALB2 pathogenic variants has been identified in 0.66–0.97% of Chinese patients with breast cancer unselected for predisposing factors (Zhang et al. 2017; Wu et al. 2020; Zhou et al. 2020; Fu et al. 2021), 0.40%–0.86% in other Asian cohorts (Japan (Momozawa et al. 2018) and Malaysia (Yang et al. 2017)), and 0.87% in Caucasian population (Couch et al. 2017). Here, PALB2 is linked to breast cancer.